O-023 Did the prognosis of MDS patients improve during the last 30 years?

and a therapeutic benefit for demethylating agents (DMA) in this group of patients (Fenaux et al., 2009). Purpose: The present study was designed to describe and analyze clinical features, prognosis and therapeutic strategies in a retrospective, multicentric German cohort study. Materials and Methods: To date, 197 patients with -7/del(7q) were included. The data was coalesced from the Universities of Dusseldorf (n=119), Freiburg (n=31), Munich (n=15), Gottingen (n=15), Dresden (n=13) and Mannheim (n=4). The median age of patients was 66 years, 63% were males. The treatment was classified as followed: Best supportive care (BSC), low-dose Chemotherapy (LDC), high-dose chemotherapy (HDC), demethylating agents (DMA) and others. Results: An isolated momosomy 7 was observed in 37%, monosomy 7 accompanied by one other abnormality in 17% and monosomy 7 within complex abnormalities in 46%. In total, -7 was observed in 125 (64%) patients, while 72 patients (36%) showed del(7q). As compared to an independent cohort of patients without monosomy 7, the mean Hb and ANC did not show a pronounced difference, while the mean platelet count (113×103/ml in -7/del(7q) versus 168×103/ml in other abnormalities; p<0.01) and bone marrow blast count (11.1%vs. 7.6%; p<0.01) differed significantly. The median survival in untreated patients with isolated -7 (n=20) was 12.5 months and 33.9 months (n=18) in del 7q (p=0.029). The majority of patients were treatedwith best supportive care (BSC; 54.3%). As the first line therapy, 21 patients (10.7%) received an allo-Tx, 7 (3.6%) HDC, 3 (1.5%) LDC, 43 (21.8%) DMA and 16 (8.1%) were treated with other therapies. Patients with any kind of therapy had a better outcome as compared to those treated with BSC exclusively (OS 25.4 months vs. 10.0 months in BSC; p=0.019). Patients who received DMA at any course of their disease showed a median survival of 25.4 months as compared to 10.0 months in patients treated with BSC (p=0.026). As expected, the best prognosis was observed in patients eligible for allo-Tx: The median OS in transplanted patients was 52.5 months. Conclusions: Patients with monosomy 7 show distinct clinical features, prognostic impact and response to therapy. Here, we present updated results of the German monosomy 7 cohort. The study is supported by research funding from Celgene